Re-Entering Antibacterial Drug Development Summit

Register by August 1 and Save $400 


Several factors including diminishing financial return, lack of new discovery platforms and others, had a cooling effect on pharmaceutical companies’ activity in the area of antibacterial drug development. At the same time, we are witnessing the wide spread of resistant bacteria, leading to untreatable infections. “We are facing a huge crisis worldwide not having an antibiotics pipeline,” said Dr. Janet Woodcock, Director of CDER at FDA, in her recent interview to NYT. The governments of European countries and the United States have created several incentives for the industry to rise to the challenge. Therefore, many companies are exploring the opportunities to start or re-open their antibacterial departments, or to stimulate the existing research and development. Cambridge Healthtech Institute is pleased to present its inaugural Re-Entering Antibacterial Drug Development Summit that includes a science track and a business track, and features a wide range of pivotal issues. The Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders shaping the current state of antibacterial discovery and development.


2014 Targeting Key Antibacterial R&D Challenges 

New discovery platforms, novel screens and approaches are needed to develop new antibacterials and stop the dangerous trends of multidrug microbial resistance. The Targeting the Key Antibacterial R&D Challenges conference, part of Re-Entering Antibacterial Drug Development Summit, is designed to serve as a scientific hub for researchers in industry and academia working on new antibiotics. Among the topic to be discussed there are gram negatives, pathogen-specific drug development, antibacterial biologics, mechanisms of resistance, clinical microbiology and others. Top industry and academia researcher are on the faculty of the meeting.  



David HooperDavid C. Hooper, M.D., Professor of Medicine, Harvard Medical School; Chief, Infection Control Unit, Associate Chief, Division of Infectious Diseases, Massachusetts General Hospital

Steven ProjanSteven J. Projan, Ph.D., Senior Vice President, R&D, Innovative Medicines, Head, Infectious Disease & Vaccines MedImmune



  • Gram Negatives at The Top Of The Unmet Needs List 
  • Antibacterial Biologics 
  • The Bacterial Resistance Portfolio 
  • Sterilizing Antibiotics 
  • Technology To Serve Antibacterial R&D 

2014 Solving The Antibacterials Commercialization Equation 

One of the major factors led to the current state of antibacterial drug development is diminishing financial return and high commercialization risks of new antibiotic development. Many pharma companies left the field in the past decade due to that reasons. In the face of growing unmet needs of new antibiotics and wide spread of multidrug resistance bacteria governments and industry are trying to get together and find the ways to make the clinical development of antibiotics easier and the overall antibiotic development profitable again. Solving The Antibacterials Commercialization Equation conference, part of Re-Entering Antibacterial Drug Development Summit, aims to encourage this dialogue. 



Timothy HuntTimothy D. Hunt, Senior Vice President, Public Affairs, Cubist Pharmaceuticals

Melissa StundickMelissa Stundick, Ph.D., Branch Chief, BARDA’s Broad Spectrum Antimicrobial Program



  • Antibacterial Market Environment And Market Access Strategy 
  • Early Pricing Planning And Negotiations for A Product in Clinical Development 
  • Improving The Economics In The Antibiotic Market 
  • The Changing Landscape of Antibacterial Drug Development: The Role of Rapid Diagnostics 
  • Venture Capital Panel Discussion 

October 28 Dinner Short Course:

Funding Opportunities for Antibacterial Research 




Targeting Key Antibacterial R&D Challenges | Solving The Antibacterials Commercialization Equation 


By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs